诺和诺德已在新泽西联邦法院对礼来提起诉讼，指控礼来为其用于减重的GLP-1药物投放广告，声称这些药物疗效优于诺和诺德的竞品药物。诺和诺德请求法院叫停相关广告并要求采取纠正措施，还要求获得金额未披露的经济赔偿。诉讼提到的一则电视广告将礼来的Zepbound与Wegovy并列比较，声称使用Zepbound者平均减重50磅，而使用Wegovy者平均减重33磅。不过，这一说法基于一项较早的临床试验，该试验比较的是Zepbound最高剂量与当时可用的Wegovy最低剂量。诺和诺德称，其较新的更高剂量Wegovy(7.2毫克)数据显示，平均减重为47磅，这一幅度与Zepbound的减重效果“临床上一致”。诺和诺德称，礼来的广告宣传活动剥夺了消费者作出知情决策所需的真实、最新和完整信息，而这些信息关系到他们可选择的治疗方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.